Navigation Links
Boston Scientific Begins PLATINUM PLUS Trial for PROMUS(R) Element(TM) Stent System
Date:5/25/2010

an," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, competitive offerings, product performance and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statem
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
4. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. Boston Scientific Announces Election of Ray Elliott to Its Board of Directors
7. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
8. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
9. Genzyme Begins Major Expansion of Boston Manufacturing Facility
10. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
11. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... DUBLIN, Ireland , August 21, 2014 ... and Markets ( http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the ... Market 2014-2018"  report to their offering.  ... also known as hormone therapy, is a ... longer being produced by the body. This ...
(Date:8/21/2014)... , Aug. 21, 2014 Mathematic studies at the ... University , and funded by the Jeffrey Epstein VI ... tumors can be visually identified for elimination. These aggressive cells ... study, which shows a topological map of what to look ... cancer research, for while tumor cells can be extracted from ...
(Date:8/21/2014)... Ontotext S4 , The Self Service Semantic ... Now the same enterprise hardened text mining, Linked Data ... is available to start-ups and mid-size businesses at a ... do not have resources to evaluate and prototype enterprise ... there is no need for on premise hardware provisioning ...
(Date:8/20/2014)... of patented university inventions licensed to biotechnology firms ... commercialization. To open these roadblocks, the researchers suggest ... the discovery stage could lead to faster commercialization ... derived from discoveries made in university laboratories and ... during clinical trials, which have a high failure ...
Breaking Biology Technology:Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... elected mayor of Colorados largest city, businessman John Hickenlooper invited ... was to ceremoniously bury the hatchet of intra-regional rivalry and ... metropolitan area, or not at all. , ,Every suburban ... a near-unanimous effort to pass a $4.7-billion mass transit initiative ...
... data quality firm Firstlogic for about $69 million ... second quarter. , ,Firstlogic is a privately held firm that ... sure their data is as correct as they need to ... call centers, web sites, customer relationship management systems, and business ...
... settled with a Belgian company that sued last September ... virus genotyping technology from Innogenetics, for undisclosed financial terms. ... Aril 2004 Third Wave forged a deal under which ... line of products in Europe. It was Third Wave's ...
Cached Biology Technology:Economic collaboration in Denver sets tall goal for Wisconsin 2Economic collaboration in Denver sets tall goal for Wisconsin 3
(Date:8/20/2014)... Oklahoma Medical Research Foundation a five-year, $14.5 million grant ... effects on humans. , For 10 years, OMRF ... the human immune response to anthrax bacteria as part ... funding came soon after anthrax-laced letters killed five and ... of Sept. 11, 2001. , The long-term goal ...
(Date:8/20/2014)... athletes who have suffered concussions ready to return to ... that high school athletes who head back on the ... significant regression in their abilities to simultaneously walk and ... in changes in their balance and/or altered walking speed, ... the 12 had returned to activity in less than ...
(Date:8/20/2014)... Biting into a chili pepper causes a burning spiciness ... Scientists exploring the chili pepper,s effect are using their ... kinds of pain, which can be caused by inflammation ... compound, which is being tested in clinical trials, in ... Tafesse and colleagues explain that decades ago, scientists had ...
Breaking Biology News(10 mins):$14.5 million grant awarded to continue anthrax studies 2Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... March 30, 2012 The Phoenix Community Alliance (PCA) ... Genomics Research Institute (TGen), with its most prestigious award. ... City Starr Award for his work in improving the ... studying diseases such as Alzheimer,s, diabetes and many types ...
... FL, March 30, 2012 The National Institutes of Health ... the role of a pathway in the development and maintenance ... immune system and turns normal disease fighting cells into cancers. ... part of our white blood cells. John Cleveland, ...
... Bethesda, MD FASEB MARC (Maximizing Access to ... for the 2012 American Society for Clinical Investigation/Association of ... April 27-29, 2012. These awards are meant to ... scientists into the mainstream of the basic science community ...
Cached Biology News:Phoenix Community Alliance honors TGen's Dr. Jeffrey Trent 2Scientists win $2 million to study new pathway in development and maintenance of lymphoma 2